3 results match your criteria: "23543Kaiser Permanente - Los Angeles Medical Center[Affiliation]"
Int J STD AIDS
December 2022
23543Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Background: Tenofovir-Emtricitabine (TDF-FTC) is known to cause bone loss in about 1-3% of HIV treated patients. Current studies lack evidence in minority groups and long-term bone loss effects in PrEP patients.
Setting: To address the risk of osteopenia/osteoporosis in patients on TDF-FTC therapy for HIV PrEP and to address the breakthrough incidence of HIV.
Am Surg
October 2022
Department of Surgery, 23543Kaiser Permanente - Los Angeles Medical Center, Los Angeles, CA, USA.
Purpose: Enhanced recovery pathways (ERPs) are associated with reduced complications and length of stay. The validation of the I-FEED scoring system, advances in perioperative anesthesia, multimodal analgesia, and telehealth remote monitoring have resulted in further evolution of ERPs setting the stage for same day discharge (SDD). Pioneers and early adopters have demonstrated the safety and feasibility of SDD programs.
View Article and Find Full Text PDFJ Intensive Care Med
December 2022
David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Previous studies evaluating patients in the Intensive Care Unit with lactic acidosis determined that the anion gap is an insensitive screening tool for elevated blood lactate. No prior study has examined the relationship between anion gap and serum lactate within the first hours of the development of lactic acidosis. Data were obtained prospectively from a convenience sample of adult trauma patients at a single level 1 trauma center.
View Article and Find Full Text PDF